Why the study?
MINOCA attributable to SSc-related CMD confirmed by invasive coronary function testing and CMR is not widely reported.
Does vasodilator therapy improve symptoms and CMR abnormalities in a patient with systemic sclerosis-associated MINOCA driven by coronary microvascular dysfunction?
Population
One 76-year-old woman with SSc and interstitial pneumonia presenting with MINOCA
Design
Case report
Follow-up
1 year
Key result
Treatment with a calcium-channel blocker and nicorandil normalized symptoms and CMR abnormalities at 3 months in a 76-year-old woman with SSc-associated MINOCA and CMD (IMR 30.5; CFR 1.7).
Authors
Loading...
Supports vasodilator reversibility in SSc-MINOCA; hypothesis-generating and requires prospective trials.
Case Report (n=1)
Does vasodilator therapy improve symptoms and CMR abnormalities in a patient with systemic sclerosis-associated MINOCA driven by coronary microvascular dysfunction?
Comprehensive invasive coronary function testing and serial CMR can diagnose and document the reversibility of systemic sclerosis-associated MINOCA driven by coronary microvascular dysfunction when treated with vasodilators.
Ohga et al. (2026) conducted a case report in Myocardial Infarction With Nonobstructive Coronary Arteries (MINOCA) associated with Systemic Sclerosis (n=1). Calcium-channel blocker and nicorandil was evaluated. Treatment with a calcium-channel blocker and nicorandil normalized symptoms and CMR abnormalities at 3 months in a 76-year-old woman with SSc-associated MINOCA and CMD (IMR 30.5; CFR 1.7).